TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male 18 years or older~* Histopathologically-proven PCa~* Unfavorable IR to HR disease:~  * Prostate specific antigen (PSA) \>= 10 ng/mL~ * Or cT-stage \>= 2b~ * Or Gleason grade 3 (4+3=7) or higher~ * Or Gleason grade 2 (3+4=7) AND \>= 50% positive biopsy cores~ * Or Decipher Score \>= 0.45~* Treating radiation oncologist intends to incorporate PSMA PET findings into the radiotherapy plan, if patient undergoes PSMA PET (intervention arm 2)~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~Exclusion Criteria:~* Less than 18 years old at the time of investigational product administration~* Extra-pelvic metastasis (M1 disease) on any imaging or biopsy done before randomization~* Prior PSMA PET~* Prior pelvic RT~* Contraindications to radiotherapy (including active inflammatory bowel disease)~* Concurrent or prior surgery or systemic therapy for PCa at the time of randomization

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (dRT) (Type: ACTIVE_COMPARATOR): 150 Patients undergo standard dRT at the discretion of the treating radiation oncologist. Patient does not undergo PSMA PET for RT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. No other primary treatment can be given before dRT. If a patient assigned to the control arm undergo a PSMA PET scan at another institution he will be discontinued from the study.
- Arm II (18F-DCFPyL, PET/CT, dRT) (Type: EXPERIMENTAL): 162 Patient undergoes PSMA PET with 18F-DCFPyL for dRT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives PSMA PET results and images. No other primary treatment can be given before RT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Taken at least one dose of double-blind medication during study IH 001 and either completed study IH 001 or were withdrawn due to reasons other than an AE considered related to study treatment~2. Male or female subjects on active haemodialysis, aged 18 years or over~3. Willing to abstain from taking any phosphate binder or oral magnesium-, aluminium-, or iron-containing products and preparations, other than the study medication;~4. Willing to avoid any intentional changes in diet such as fasting, dieting or overeating;~5. Willing to maintain their usual type and dose of Vitamin D supplementation.~Exclusion Criteria:~1. Participation in any other clinical trial using an investigational product or device within the previous 4 months;~2. A significant history of alcohol, drug or solvent abuse in the opinion of the investigator;~3. Any disease or condition, physical or psychological, which in the opinion of the investigator would compromise the safety of the subject or increase the likelihood of the subject being withdrawn;~4. Clinically significant laboratory findings (for this subject population) in the opinion of the investigator.~5. Any malignancy with the exception of basal cell carcinoma;~6. A history of a motility disorder of the intestines, including, but not limited to, gastroparesis, ileus, pseudo-obstruction, megacolon, or mechanical obstruction;~7. A significant illness in the 4 weeks before screening;~8. Taking medication for seizures;~9. A history of haemochromatosis;~10. A history of serum ferritin concentration of ≥ 1000 ng/mL (excluding transient, treatment-induced ferritin elevation);~11. A history of dysphagia or swallowing disorders;~12. Female subjects who are lactating or pregnant. Women of childbearing potential (pre-menopausal and not surgically sterilised) unless they abstain from sexual intercourse or are using a reliable contraceptive method, that is, barrier methods, hormones or intrauterine device;~13. Current haemoglobin concentration of \< 10.00 g/dL;~14. Allergy to the IMP or its constituents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fermagate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pathophysiological Study of Characteristics of the Changes in the Cutaneous Immune System After Intradermal Antigen Injections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Both genders eligible for study.~* Female participants must use a contraceptive method.~* Tuberculin skin test between 1 and 15mm~* Participants must be able to understand and sign the Informed Consent, and comply with all aspects of the protocol.~* Subjects registered in a social security system or with health insurance cover~* First group: Healthy subjects aged from 18 to 75 years with 2 subgroups: 18-40 and 60-75 year old subjects~* Second group: Patients with kidney transplants of longer than 6 months on immunosuppressive treatment~Exclusion Criteria:~* Pregnant or lactating women.~* Previous allergic reaction to tuberculin skin test~* Active skin disease on testing zone~* Patients with a clinically significant disease (chronic, recurrent or active)~* Local or systemic medication which interacts with the outcome measures.~* Patients deprived of their civic rights, in custody, or under the care of a tutorial, judiciary or administrative body.~* Patients relevant of a protection measure~* Patients in a critical medical situation~* Patients with a personal situation evaluated by the investigator as unable to give an optimal participation in the study, or where it could constitute a risk for the patient~* Linguistic barrier or psychological profile disabling the patient from signing the consent form~* Patient still in an exclusion period following participation in another clinical trial~* Patients having earned more than 4500€ in indemnities following participation in clinical trials during the last 12 months, including this study~For group 1 only:~* Systemic corticotherapy or immunosuppressive treatment within the 2 weeks before first visit or within 2 weeks before the third visit or the biopsies.~* Systemic non anti-inflammatory drugs the week before the first visit or within 1 week before the third visit or the biopsies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study Into the Effect of Seprafilm in Open Total Thyroidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21-75~* Histological confirmation of differentiated thyroid cancer requiring surgery, symptomatic goiters, thyroid nodules requiring histological analysis, or thyrotoxicosis poorly controlled by medication.~* Undergoing total thyroidectomy~Exclusion Criteria:~* Previous neck surgery~* Previous neck radiotherapy~* Patients with a known history of keloids~* Patients with a known history of motility disorders in the upper gastrointestinal tract and preexisting swallowing difficulty.~* Patients with metastatic disease; patients with disease that would require postop radiation therapy, radionuclide iodine therapy and any adjuvant therapies.~* Patients with advanced disease that would require radical or modified neck dissection~* Patients with lobe larger than 10 cm, or nodule larger than 8 cm which require extensive dissection that may confound the study~* Patients with connective tissue diseases and chronic diseases on long-term medications that may interfere with wound healings such as steroids

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Seprafilm (Sanofi, USA) (Type: ACTIVE_COMPARATOR): Patients in this arm received Seprafilm during surgery.
- Control (Type: NO_INTERVENTION): Patients in this arm does NOT receive Seprafilm during surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Undergoing cardiac surgery, able to consent, and at least one of the following:~  * Age \>65 years~ * ejection fraction \<=40%~ * diabetes mellitus (insulin requiring and non-insulin requiring)~ * peripheral vascular disease~ * creatinine \>=2 mg/dl~ * body surface area \>= 2 sq meters~ * endocarditis~ * albumin \<=2.5 g/dl~ * on antibiotics for any reason other than operative prophylaxis~Exclusion Criteria:~* Unable to consent~* Not meeting inclusion criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Expanding Access to Comprehensive Geriatrics Care Via Telehealth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans discharged from the Indianapolis VA medical center (VAMC) for an medical/surgical diagnosis (excludes substance use disorder-related admissions; excludes planned admissions) within the prior week~* Age 70 years~* Not enrolled in home-based primary care (HBPC)~* Not enrolled in hospice~* Not in dialysis~* Primary care visit within VA in the prior 2 years~* Not residing in nursing home, skilled nursing facility, or CLC.~* Living \>20 miles but \<60 miles from the Indianapolis VAMC facility~* CAN score 95th percentile for mortality or missing CAN score~* Discharged from the hospital alive~Exclusion Criteria:~* Patients who have been randomized to the control arm after their index hospitalization who become readmitted to the hospital may not be re-randomized.~* By definition, GRACE patients are not eligible for TeleGRACE due to the drive distance \>20 miles from the Indianapolis VAMC~* Enrolled in home-based primary care (HBPC)~* Enrolled in hospice~* Dialysis (hemodialysis or peritoneal dialysis)~* Residing in nursing home, skilled nursing facility, or CLC.~* Living \<20 miles or 60 miles from the Indianapolis VAMC facility

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TeleGRACE (Type: EXPERIMENTAL): Patients receive a virtual home visit and care from the GRACE team
- Usual Care (Type: NO_INTERVENTION): Patients receive usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Therapy Process With Movement Strategies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults over the age of 18~2. Ability to read and provide informed consent~3. Current patient or therapist at the Center for Anxiety and Related Disorders (CARD)~4. Ability to complete exercise (e.g. no physical injuries)~Exclusion Criteria:~1. Participants considered high risk based on the ACSM risk stratification guidelines (derived from PAR-Q)~2. Participants with current knee, ankle, hip, or foot injuries that could impede exercise on the machine or participants with current hand or wrist injuries that could impede use of the worry stone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: OTHER): First session: worry stone, second session: exercise peddler
- Group 2 (Type: OTHER): First session: exercise peddler, second session: worry stone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Ambulatory outpatients with breast (including ductal carcinoma in situ \[DCIS\]) cancer.~2. Patients to be treated with RT for curative intent.~3. Women ≥18 years of age.~4. Eastern Cooperative Oncology Group (ECOG) performance status \<3 (Appendix 4).~5. Hemoglobin ≥ 9 g/dL~6. Either post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control during study treatment and for 3 months afterwards.~7. Subjects who are currently taking melatonin must discontinue melatonin for 5 days before enrolling in the study.~8. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria~1. Fatigue brought on by conditions other than cancer such as (the indicated tests are required only if that mechanism of fatigue is suspected):~   * uncontrolled hypothyroidism (TSH \>10 IU)~  * hypercalcemia (calcium \>11 mg/dL) Calcium (Ca) = Serum Calcium (SerumCa) + 0.8 \* (NormalAlbumin - PatientAlbumin)~  * decompensated congestive heart failure~  * chronic obstructive pulmonary disease requiring oxygen replacement~2. Patients with a creatinine clearance \<30 mL/min~3. Aspartate aminotransferase (AST) \> 3X upper limit of normal (ULN)~4. Alanine aminotransferase (ALT) \> 3X ULN~5. Bilirubin \> 1X ULN~6. Use of systemic steroids, or other pharmacological agents such as methylphenidate for cancer-related fatigue~7. Current use of American ginseng, remelteon, or warfarin.~8. Depression ≥ grade 2 (CTCAE v4.0)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 20 mg Melatonin (Type: ACTIVE_COMPARATOR): RT (as clinically indicated) + melatonin (Subjects will receive 20-mg oral melatonin the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
- Placebo (Type: PLACEBO_COMPARATOR): RT (as clinically indicated) + placebo (Subjects will receive 20-mg oral placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients with locally advanced breast cancer (cT3-4c, N0-3) with tumors \> 5 cm, as determined by MRI, where the present guidelines include them for neoadjuvant systemic therapy~* Written informed consent (informed consent document to be approved by the Independent Ethics Committee) prior to study-related procedures and examinations.~* Female age \> 18 years~* Able to comply with the protocol~* Histologically confirmed adenocarcinoma of the breast~* American Society of Anesthesiologist's physical status category 1 or 2 before surgery. Category 1 and 2 includes healthy patients and patients with only mild systemic disease, whereas category 3 includes patients with more serious systemic diseases (but still operable).~Exclusion criteria:~* Inflammatory breast cancer or diffuse locoregional involvement of the skin~* Stage IV - metastatic disease~* Locoregional relapse of earlier breast cancer~* Inability (irrespective of reason) to receive the recommended neoadjuvant treatment, - as decided by the treating physician.~* American Society of Anesthesiologist's physical status category 4-5

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 75 years~* Patients undergoing shoulder procedures, such as rotator cuff repair, capsular shift, shoulder arthroplasty, subacromial decompression~Exclusion Criteria:~* Contraindications to interscalene block (Coagulopathy, infection at the needle insertion site, moderate to severe chronic obstructive pulmonary disease, contralateral pneumothorax or diaphragmatic paralysis)~* Pregnancy~* Pre-existing neuropathy involving the surgical limb~* Systemic glucocorticoid treatment (for 2 weeks or more) within six months of surgery~* Chronic opioid use (greater than 30 mg oral oxycodone equivalent per day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: PLACEBO_COMPARATOR): Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
- Group 2 (Type: PLACEBO_COMPARATOR): Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
- Group 3 (Type: ACTIVE_COMPARATOR): Group 3 Ropivacaine and dexamethasone: 30 ml 0.5% ropivacaine mixed with dexamethasone 8 mg (2 ml)
- Group 4 (Type: ACTIVE_COMPARATOR): Group 4 Bupivacaine and steroid: 30 ml 0.5% bupivacaine mixed with dexamethasone 8 mg (2 ml).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with stage IV non-squamous non-small-cell lung cancer (NSCLC) who have not been previously treated with systemic therapy for metastatic disease, and meet all of the following:~1. Signed and dated NGS Informed Consent Form (ICF) by the patient (or legally acceptable representative (LAR), if applicable).~2. Biopsy-confirmed OR clinically suspected stage IV NSCLC not previously treated with systemic therapy for metastatic disease.~3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~4. Age ≥ 18 years old on the day of signing informed consent.~5. Estimated life expectancy \> 3 months.~6. At least one radiographically measurable lesion per RECIST v1.1 defined as a lesion that is ≥ 10 mm in longest diameter or lymph node that is ≥ 15 mm in short axis imaged by computed tomography (CT) scan or magnetic resonance imaging (MRI).~7. Clinically eligible to receive standard-of-care combination therapy with pemetrexed + carboplatin + Pembrolizumab (PCP) for stage IV disease.~Exclusion Criteria:~Any contraindication to pemetrexed, carboplatin, and Pembrolizumab treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biomarker Screening (Type: None): Patients with stage IV nonsquamous NSCLC not previously treated with systemic therapy for metastatic disease and who meet all of study inclusion criteria and none of the exclusion criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy